diagnostic services
 


New Test Release!
The miR-31now enables clinicians to identify patients for which first-line anti-EGFR treatment will be of greater clinical benefit versus anti-VEGF therapy or when second or further lines of treatment with anti-EGFR therapy is beneficial to patients with mCRC. Low miR-31-3p expression levels predicts survival benefit with cetuximab in RAS wild-type (WT) metastatic colorectal cancer patients receiving FOLFIRI therapy.5,6
 
Low miR-31-3p expression favors first-line treatment with cetuximab for RAS WT mCRC patients.5,6
High miR-31-3p expressors have no difference in outcomes when treated with anti-EGFR or anti-VEGF therapy.5,6
The RT-qPCR miR-31now test has been developed and technically validated to measure miR-31- 3p expression levels in FFPE specimens from metastatic colorectal cancer tumors.7

RESULTS FROM PROSPECTIVE-RETROSPECTIVE STUDY 

https://drive.google.com/file/d/1m-MHrudeDMi6vw7ADWBLA95wd9z4Ui3M/view?usp=sharing
miR-31-3p expression was measured in primary tumors from 340 RAS WT patients with metastatic colorectal cancer enrolled in the FIRE-3 trial. Patients were split into low or high miR-31-3p expression subgroups according to a pre-defined cut-off.
 
Results from the study demonstrated that RAS WT mCRC patients with low miR-31-3p expression treated with cetuximab had a:

•  40% risk reduction for death when treated with cetuximab compared to bevacizumab.
•  12 month longer median overall survival when treated with cetuximab versus bevacizumab.

There was no difference in survival outcomes between cetuximab and bevacizumab in patients with high miR-31-3p expression.
 

 The results of this study demonstrate that low miR-31-3p expression levels predicts survival benefit with cetuximab in RAS WT metastatic colorectal cancer patients receiving FOLFIRItherapy.5,6


Additional data from the study:

There was a significantly higher investigator-assessed objective response in patients with low miR-31-3p expression treated with cetuximab + FOLFIRI vs. bevacizumab + FOLFIRI.  OR = 4.49 [2.07 ; 9.76], p=0.0001
Odds ratio [95% CI] adjusted on age, number of organs and BRAF status. Excludes patients with missing data.
https://drive.google.com/file/d/1JocMNPhxmR6VYs0BMrfjJamklbrvhBjH/view?usp=sharing
 
 
 
 
 
 




Depth of response (DoR) for patients treated with cetuximab + FOLFIRI was significantly correlated with miR-31-3p expression levels. 
There was no correlation observed between DoR and miR-31-3p expression in patients treated with bevacizumab + FOLFIRI.
https://drive.google.com/file/d/1rhc0TNWwDI_ORu-2Vlx_CFWAibFTqPPH/view?usp=sharing
 
 
 
 
 
 
 

Study conclusions:

•  Low miR-31-3p expression favors first-line treatment with cetuximab for RAS WT mCRC patients.5,6
•  High miR-31-3p expressors have no difference in outcomes when treated with anti-EGFR or anti-VEGF therapy.5,6
 
Click here to review the results of additional studies  which have demonstrated the predictive effect miR-31-3p expression has on response to EGFR inhibitors in patients with mCRC.
 
References:
1. Manceau G, Imbeaud S, Thiébaut R, et al. Clin Cancer Res. 2014; 20: 3338-47.
2. Mosakhani N, Lahti L, Borze I, et al. Cancer Genet. 2012; 205: 545-51.
3. Laurent-Puig P, Bridgewater JA, Primrose JN, et al. J Clin Oncol. 2015; 32: (suppl; abstr 3523).
4. Laurent-Puig P, Paget-Bailly S, Vernerey D, et al. J Clin Oncol. 2015; 33: (suppl; abstr 3547).
5. Laurent-Puig P, Grisoni ML, Heinemann V, et. al. J Clin Oncol . 2016; 34 (suppl; abstr 3516).
6. Data on file.